Guideline Summary: Evaluation and Management of Secondary Amenorrhea in Adolescents

Initial Diagnostic Evaluation

• Serum β‑hCG testing is required to definitively exclude pregnancy, because urine tests can be falsely negative in rare situations such as ectopic pregnancy. 1
• A complete metabolic panel (CBC, electrolytes, glucose, renal and liver function tests) should be obtained to screen for systemic illness, malnutrition, or eating disorders. 1
• TSH and free T4 measurement is essential to rule out thyroid dysfunction, a common cause of menstrual cycle disruption. 1
• Morning fasting prolactin should be measured; levels >20–25 µg/L indicate prolactin‑mediated anovulation. 1
• FSH, LH, and estradiol drawn on cycle days 3–6 (or any time during amenorrhea) differentiate hypothalamic/pituitary disorders from ovarian insufficiency. 1
• Testosterone and DHEA‑S are screened when clinical signs of hyperandrogenism (hirsutism, acne, virilization) are present. 1
• Anti‑Müllerian hormone (AMH) assists in assessing ovarian reserve and supports a PCOS diagnosis when clinically appropriate. 2
• A detailed history of diet, eating‑disorder behaviors, and weight changes is crucial because restrictive eating and low energy availability are strongly linked to functional hypothalamic amenorrhea. 3
• Exercise intensity >12 hours/week or participation in low‑weight sports (e.g., gymnastics, distance running) markedly increases the risk of secondary amenorrhea. 3
• Psychological stressors, perfectionism, mood disorders, and sleep disturbances activate the HPA axis and suppress GnRH secretion. 3
• Menstrual cycles consistently >45 days warrant evaluation even before three months of complete amenorrhea. 3
• A history of stress fractures (up to 30 % in ballet dancers) signals low bone mass from energy deficiency and should prompt bone health assessment. 3
• Galactorrhea, headaches, or visual changes suggest hyperprolactinemia or a pituitary adenoma and require further neuro‑imaging work‑up. 1
• Vital‑sign findings of bradycardia and cool extremities are clinical clues to functional hypothalamic amenorrhea. 4
• External genital examination (and bimanual exam if sexually active) is needed to exclude anatomic abnormalities such as imperforate hymen or vaginal septum. 1
• Signs of hyperandrogenism (Ferriman‑Gallwey score ≥4–6, acne, androgenic alopecia) indicate possible PCOS. 5
• Acanthosis nigricans serves as a marker of insulin resistance in adolescents with suspected PCOS. 5

Diagnostic Patterns Based on Laboratory Results

• Low‑normal FSH/LH (<10 IU/L) with low estradiol (<50 pg/mL) points to functional hypothalamic amenorrhea or central hypogonadism. 3
• Functional hypothalamic amenorrhea is a diagnosis of exclusion; other endocrine, anatomic, and organic causes must be ruled out first. 3
• Validated screening tools for eating disorders, excessive exercise, and psychological stressors should be employed in suspected functional hypothalamic amenorrhea. 3
• Bone‑density assessment (DEXA) is recommended when hypoestrogenism is prolonged, as it can cause low bone mass, stress fractures, and impaired peak bone accrual. 3
• Pelvic ultrasound is indicated to exclude Müllerian anomalies or intrauterine adhesions, especially after a history of postpartum curettage or pelvic infection. 6
• Elevated FSH (>25–35 IU/L) with low estradiol identifies primary ovarian insufficiency; AMH <0.5–1 ng/mL confirms diminished ovarian reserve. 7
• An LH/FSH ratio >2 together with normal or elevated testosterone suggests polycystic ovary syndrome (PCOS). 5
• PCOS diagnosis requires clinical or biochemical hyperandrogenism (hirsutism, acne, elevated testosterone or free androgen index). 5
• Oligomenorrhea defined as cycles >35 days or <8 cycles/year persisting >2 years post‑menarche supports PCOS evaluation. 5
• Pelvic ultrasound criteria for polycystic ovarian morphology (≥12 follicles 2–9 mm per ovary or ovarian volume >10 mL) are insufficient alone for PCOS diagnosis in adolescents. 5
• Non‑classic congenital adrenal hyperplasia is excluded by early‑morning 17‑hydroxyprogesterone >200 ng/dL, followed by ACTH stimulation testing if positive. 5
• Metabolic‑syndrome screening (fasting glucose, 2‑hour OGTT, lipid panel, blood pressure) is recommended in adolescents with PCOS. 5
• Prolactin >20–25 µg/L indicates hyperprolactinemia; secondary causes such as hypothyroidism (elevated TSH) must be reassessed. 7
• Testosterone >200 ng/dL or rapid virilization raises urgent concern for an androgen‑secreting tumor; immediate pelvic ultrasound and adrenal CT are warranted. 5

Treatment Strategies by Diagnosis

Functional Hypothalamic Amenorrhea

• Goal: restore energy balance and reduce stress rather than induce withdrawal bleeding with hormones. 3
• Nutritional rehabilitation with a registered dietitian to achieve a positive energy balance. 3
• Reduce excessive exercise, especially in athletes training >12 hours/week. 3
• Cognitive‑behavioral therapy or other psychological support to address stress, perfectionism, and mood disorders. 3
• If amenorrhea persists >6 months despite lifestyle changes, initiate transdermal estradiol (physiologic dose) plus cyclic progestin for bone protection; oral contraceptives are not first‑line for bone health. 3
• Oral contraceptives mask the underlying problem and do not restore bone formation; they should be avoided as primary therapy for bone health. 3

Polycystic Ovary Syndrome

• Combined oral contraceptives are first‑line for menstrual regulation, androgen suppression, and endometrial protection. 5
• Metformin (1,500–2,000 mg daily) is second‑line, particularly effective in overweight adolescents with insulin resistance and acanthosis nigricans. 5
• Cyclic progestins (e.g., medroxyprogesterone 10 mg for 10–14 days every 1–3 months) are alternatives when contraceptives are contraindicated; they prevent endometrial hyperplasia but do not suppress androgens. 5
• Spironolactone (50–200 mg daily) can be added for persistent hirsutism unresponsive to contraceptives; it is off‑label and contraindicated in pregnancy. 5
• Lifestyle modification targeting 5–10 % weight loss (500–700 kcal/day deficit) and ≥150 min/week moderate‑intensity exercise improves metabolic parameters and may restore ovulation. 5
• Annual metabolic screening (fasting glucose, lipid panel, blood pressure) is required due to increased risk of type 2 diabetes and cardiovascular disease. 5
• Ensure withdrawal bleeding at least every 3 months to protect the endometrium. 5

Primary Ovarian Insufficiency (Limited evidence)

• Transdermal estradiol titrated to physiologic levels plus cyclic progestin is recommended to support bone, cardiovascular health, and quality of life. 7

Hyperprolactinemia (Limited evidence)

• Dopamine agonists (cabergoline or bromocriptine) are first‑line to normalize prolactin and restore ovulation. 7

Bone Health Considerations

• Adolescence is the critical window for peak bone mass; prolonged amenorrhea can cause irreversible bone loss. 3
• DEXA scanning is indicated in any adolescent with ≥6 months of amenorrhea, or earlier if severe nutritional deficiency, eating disorder, or fracture history is present. 3
• Calcium intake of 1,200–1,500 mg/day and vitamin D 600–1,000 IU/day are foundational for bone health. 3
• Weight‑bearing exercise promotes bone formation, but excessive exercise in the setting of energy deficiency worsens bone loss. 3
• Transdermal estradiol, not oral contraceptives, is preferred for bone protection in functional hypothalamic amenorrhea. 3

Follow‑Up and Monitoring

• Repeat laboratory testing at 3 months to evaluate treatment response. 5
• Annual metabolic screening (glucose, lipids, blood pressure) for adolescents with PCOS. 5
• Bone‑density reassessment every 1–2 years in functional hypothalamic amenorrhea or primary ovarian insufficiency. 3
• Ongoing psychological support throughout management, given the strong association of amenorrhea with anxiety, depression, and disordered eating. 3

Critical Pitfalls to Avoid

• Do not diagnose functional hypothalamic amenorrhea without first excluding pregnancy, thyroid disease, hyperprolactinemia, PCOS, and primary ovarian insufficiency. 3
• Do not rely on polycystic ovarian morphology on ultrasound alone to confirm PCOS in adolescents; it may represent a normal developmental variant. 5
• Do not prescribe oral contraceptives as first‑line bone protection in functional hypothalamic amenorrhea; they mask the underlying problem and do not restore bone formation. 3
• Do not dismiss oligomenorrhea persisting >2 years post‑menarche; it warrants full evaluation for underlying pathology. 3
• Do not overlook eating disorders, excessive exercise, or psychological stressors, as they are the most common causes of secondary amenorrhea in adolescents. 3

Diagnostic and Management Guidelines for Two‑Month Amenorrhea with Low Ferritin

1. Initial Diagnostic Evaluation

1.1 Endocrine Laboratory Panel

• Measure serum TSH and free T4 to exclude thyroid dysfunction, a frequent reversible cause of menstrual disruption. 8
• Obtain a morning fasting prolactin level; values > 20–25 µg/L suggest prolactin‑mediated anovulation, and levels > 100 ng/mL warrant pituitary MRI. 8
• Draw FSH, LH, and estradiol to distinguish hypothalamic/pituitary disorders from primary ovarian insufficiency. 8
• Perform a complete blood count, comprehensive metabolic panel, and inflammatory markers (ESR, CRP) to screen for chronic illness, malnutrition, or eating disorders. 8
• Assess testosterone and DHEA‑S only when clinical signs of hyperandrogenism (e.g., hirsutism, acne, virilization) are present. 8

1.2 History Elements Linked to Functional Hypothalamic Amenorrhea

• Document detailed eating patterns, weight changes, restrictive dieting, and eating‑disorder behaviors, because energy deficiency is strongly associated with functional hypothalamic amenorrhea. 8
• Evaluate psychological stressors, perfectionism, mood disorders, and sleep disturbances, which activate the HPA axis and suppress GnRH secretion. 8

2. Laboratory Patterns and Diagnostic Criteria

2.1 Functional Hypothalamic Amenorrhea (FHA)

• Low‑normal FSH/LH (< 10 IU/L) together with low estradiol (< 50 pg/mL) indicates FHA or central hypogonadism. 8
• In FHA, TSH and free T4 are typically in the lower normal range, testosterone is low‑normal, and prolactin is low‑normal. 8
• A GnRH stimulation test shows a preserved acute gonadotropin response (2‑ to 3‑fold rise in LH and FSH), differentiating FHA from organic hypogonadotropic hypogonadism. 8

2.2 Hyperprolactinemia (Relevant Threshold)

• Prolactin > 100 ng/mL mandates pituitary imaging to exclude an adenoma. 8

3. Management Strategies

3.1 Functional Hypothalamic Amenorrhea

• Nutritional rehabilitation with a registered dietitian to achieve a positive energy balance is the first‑line therapy. 8
• Cognitive‑behavioral therapy (or other psychological support) should be provided to address stress, perfectionism, and mood disorders. 8
• If amenorrhea persists > 6 months despite lifestyle modification, initiate physiologic transdermal estradiol plus cyclic progestin for bone protection (oral contraceptives are not first‑line for bone health). 8

3.2 Iron‑Deficiency Assessment and Treatment

3.2.1 Diagnostic Markers

• Ferritin < 45 µg/dL in the setting of anemia is the most sensitive indicator of iron deficiency. 9
• When ferritin is 45–100 µg/dL and inflammation is present, confirm iron deficiency with transferrin saturation, soluble transferrin receptor, or reticulocyte hemoglobin equivalent. 9
• Evaluate dietary iron intake, recent menstrual blood loss, and gastrointestinal sources (e.g., H. pylori infection) as part of the work‑up. 9

3.2.2 Oral Iron Therapy

• Ferrous iron salts (ferrous sulfate, fumarate, or gluconate) are recommended as first‑line agents because they are inexpensive and effective. 9
• Administer oral iron on an empty stomach for optimal absorption; if gastrointestinal intolerance occurs, taking it with meals is acceptable. 9
• Co‑administration with meat protein and 500 mg vitamin C enhances absorption, even in the presence of calcium or fiber. 9
• Tailor the dose and duration of oral iron to the severity of deficiency and patient tolerance. 9

3.2.3 Intravenous Iron Therapy

• IV iron should be considered for patients with severe iron deficiency or conditions that impair oral iron absorption. 9
• IV formulations are increasingly used due to poor oral‑iron tolerance (nausea, constipation) and tight regulation of intestinal iron uptake. 9

3.2.4 Gastrointestinal Evaluation

• Review recent menstrual bleeding patterns; heavy bleeding before amenorrhea is a common cause of iron deficiency in reproductive‑age women. 9
• Investigate gastrointestinal disorders (e.g., H. pylori infection, celiac disease) that can cause iron loss or malabsorption; ensure adherence to a gluten‑free diet in celiac patients. 9

Diagnostic Approach to Low Estradiol with Normal Gonadotropins

Hormonal Pattern Interpretation

• The combination of low‑normal FSH/LH (<10 IU/L), low estradiol (<50 pg/mL), and normal prolactin is characteristic of functional hypothalamic amenorrhea or central hypogonadism, and the workup must first exclude organic causes. 10

Initial Laboratory Evaluation

• Measuring serum TSH and free T4 is recommended to rule out thyroid dysfunction, which frequently disrupts menstrual cycles and can produce a similar hormonal profile. 10
• Serum testosterone and DHEA‑S should be assessed only when clinical signs of hyperandrogenism (e.g., hirsutism, acne, virilization) are present, to exclude polycystic ovary syndrome or adrenal disorders. 10

GnRH Stimulation Testing

• In functional hypothalamic amenorrhea, GnRH stimulation elicits a preserved acute gonadotropin response—typically a 2‑ to 3‑fold rise in LH and FSH from baseline—distinguishing it from organic hypogonadotropic hypogonadism. 10
• In organic hypogonadotropic hypogonadism, the acute LH response to GnRH is blunted; however, it normalizes with prolonged pulsatile GnRH therapy. 10
• Very low or undetectable baseline LH and FSH levels (rather than low‑normal) suggest an organic etiology such as genetic GnRH mutations or central lesions (pituitary/hypothalamic tumors, infiltrative disease). 10
• When estradiol remains persistently below 20 pg/mL, the GnRH stimulation test is the sole feature that definitively differentiates functional from organic causes. 10

Imaging Studies

• Brain MRI with a dedicated pituitary protocol is indicated when gonadotropins are very low/undetectable, suggesting organic central hypogonadism, or when neurological symptoms (headache, visual changes) are present. 10

Interpretation of Hormone Measurements

• A single estradiol measurement has limited diagnostic value; persistently low estradiol (<20 pg/mL) is the clinically significant threshold. 10
• In functional hypothalamic amenorrhea, gonadotropins are typically low‑normal—neither the elevated levels seen in ovarian insufficiency nor the suppressed levels of organic hypogonadotropic hypogonadism. 10
• The LH/FSH ratio may be elevated in functional hypothalamic amenorrhea, potentially mimicking polycystic ovary syndrome, but the lack of hyperandrogenism and the presence of energy deficiency or stress help differentiate the conditions. 10

Evaluation and Management of Hypothyroidism‑Induced Hypogonadotropic Hypogonadism

Hormonal Pattern Interpretation

• In women, a low‑normal luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) (< 10 IU/L) together with low estradiol (< 50 pg/mL) is indicative of functional hypothalamic amenorrhea or central hypogonadism rather than primary ovarian failure. [11][12]

Characteristics of Functional Hypothalamic Amenorrhea (FHA)

• FHA commonly occurs in the setting of energy deficiency caused by restrictive eating, excessive exercise (> 12 h/week), or marked psychological stress. 11
• Typical laboratory findings in FHA include thyroid function tests in the lower‑normal range and low‑normal prolactin concentrations. 11

Diagnostic Evaluation of Women with Hypothyroidism‑Related Hypogonadism

Thyroid Replacement Adequacy

• Serum thyroid‑stimulating hormone (TSH) and free thyroxine (free T4) should be measured to verify that levothyroxine dosing is sufficient; target TSH is generally 0.5–2.5 mIU/L. [12][13]

Prolactin Assessment

• A morning fasting prolactin level is required to exclude hyperprolactinemia as an additional suppressor of gonadotropins. 12

GnRH Stimulation Testing (if hormones remain suppressed after euthyroidism)

• GnRH stimulation testing helps differentiate functional from organic hypogonadotropic hypogonadism. A preserved 2‑ to 3‑fold rise in LH and FSH after GnRH administration confirms functional suppression; a blunted response suggests organic pituitary disease and warrants magnetic resonance imaging (MRI). [11][12]

Clinical Decision‑Making and Pitfalls

• A diagnosis of functional hypothalamic amenorrhea should not be made in a patient with confirmed autoimmune hypothyroidism until thyroid function is fully optimized and prolactin levels are normal. [11][12]

• Autoimmune hypothyroidism itself provides an organic cause of hypogonadotropic hypogonadism, making FHA a diagnosis of exclusion. [11][12]

• In FHA, thyroid function is typically low‑normal; therefore, low TSH alone does not explain the gonadal suppression seen with overt hypothyroidism. 11

All statements are supported by peer‑reviewed evidence from the cited literature.

Guideline for Evaluation and Management of Two‑Year Amenorrhea

Initial Laboratory Evaluation

• Serum β‑hCG should be obtained first to definitively exclude pregnancy before any further work‑up of prolonged amenorrhea. 14
• Simultaneous measurement of FSH and estradiol is essential to differentiate primary ovarian insufficiency (POI) from hypothalamic/pituitary disorders. An FSH > 25 IU/L with low estradiol (<50 pg/mL) confirms POI and warrants repeat testing in 1 month for diagnostic certainty. 15
• Low‑normal gonadotropins (FSH/LH < 10 IU/L) together with low estradiol suggest functional hypothalamic amenorrhea (FHA) or central hypogonadism. 14
• Thyroid function tests (TSH and free T4) must be performed because thyroid dysfunction is a common reversible cause of amenorrhea. [14][15]
• A morning fasting prolactin level screens for hyperprolactinemia; values >20–25 µg/L are abnormal, and levels >100 ng/mL mandate pituitary MRI. 14
• Anti‑Müllerian hormone (AMH) assists in assessing ovarian reserve; AMH < 0.5–1 ng/mL supports a POI diagnosis. 15

Clinical History and Physical Findings Relevant to Diagnosis

• Document eating patterns, recent weight changes, restrictive dieting, and eating‑disorder behaviors; energy deficiency is a strong predictor of FHA. 14
• Assess exercise intensity; training >12 hours/week or participation in low‑weight sports (e.g., gymnastics, distance running, ballet) markedly increases FHA risk. 14
• Screen for psychological stressors, perfectionism, mood disorders, and sleep disturbances, which activate the HPA axis and suppress GnRH secretion. 14
• A family history of POI, eating disorders, fragile X syndrome, or autoimmune diseases (thyroid, diabetes, Addison’s, celiac) should be elicited. 15
• Prior ovarian or pelvic surgery, chemotherapy, or pelvic radiation raises suspicion for iatrogenic POI. 15
• Review use of hormonal contraceptives, which can mask underlying amenorrhea and suppress FSH for ≥3 months after discontinuation. 15
• Physical signs suggestive of FHA include bradycardia and cool extremities. 14
• Signs of hypoestrogenism (thin, reddened vaginal mucosa; mottled skin; hypercarotenemia) point toward estrogen deficiency. 14
• Galactorrhea indicates hyperprolactinemia; visual field defects, papilledema, or headaches raise concern for a pituitary adenoma. 14
• Thyromegaly suggests underlying thyroid disease. 14

Diagnostic Algorithms

Primary Ovarian Insufficiency (POI)

• Laboratory pattern: Elevated FSH > 25 IU/L + low estradiol. Confirm with repeat testing after 1 month. 15
• Adjunctive tests: AMH < 0.5–1 ng/mL confirms diminished ovarian reserve; screen for autoimmune antibodies, fasting glucose, morning cortisol, anti‑tissue transglutaminase, calcium/phosphate; perform karyotype (to detect Turner syndrome or mosaicism) and FMR1 premutation testing when indicated. 15
• Management: Initiate physiologic transdermal estradiol with cyclic progestin for bone, cardiovascular, and neurocognitive protection; counsel that ovarian function may be unpredictable and spontaneous pregnancy remains possible. 15

Functional Hypothalamic Amenorrhea (FHA) / Central Hypogonadism

• Laboratory pattern: Low‑normal FSH/LH (<10 IU/L) + low estradiol. Diagnosis of exclusion after ruling out pregnancy, thyroid disease, hyperprolactinemia, PCOS, and POI. 14
• Progestin challenge test: Administration of medroxyprogesterone (10 mg for 10 days) induces withdrawal bleeding if estrogen exposure is sufficient and confirms outflow tract integrity. 14
• Neuroimaging: Brain MRI with pituitary protocol is indicated when gonadotropins are very low/undetectable, neurological symptoms are present, or prolactin is elevated. 14
• Bone health: Perform DEXA scanning when hypoestrogenism persists ≥6 months, as prolonged amenorrhea leads to irreversible bone loss. 14

Hyperprolactinemia

• Laboratory pattern: Prolactin >20–25 µg/L. Re‑measure TSH and free T4 to exclude secondary hyperprolactinemia from hypothyroidism. [14][15]
• Imaging threshold: Prolactin >100 ng/mL mandates pituitary MRI to rule out adenoma. 14

Management Strategies

Functional Hypothalamic Amenorrhea

• First‑line: Nutritional rehabilitation with a registered dietitian to achieve a positive energy balance. 14
• Reduce excessive exercise, especially in athletes training >12 hours/week. 14
• Provide cognitive‑behavioral therapy or psychological support to address stress, perfectionism, and mood disorders. 14
• If amenorrhea persists >6 months despite lifestyle modification, start physiologic transdermal estradiol plus cyclic progestin for bone protection. 14
• Supplement calcium (1,200–1,500 mg/day) and vitamin D (600–1,000 IU/day) as foundational therapy.

Primary Ovarian Insufficiency

• Transdermal estradiol titrated to physiologic levels with cyclic progestin for bone, cardiovascular, and neurocognitive protection. 15
• Counsel patients that ovarian function may be intermittent and spontaneous conception remains possible; discuss contraception if pregnancy is not desired. 15
• Conduct annual screening for associated autoimmune conditions (thyroid antibodies, adrenal, celiac, etc.). 15

Critical Pitfalls to Avoid

• Do not diagnose FHA without first excluding pregnancy, thyroid disease, hyperprolactinemia, PCOS, and POI. 14
• Do not rely on a single FSH measurement for POI; repeat testing after 1 month is required. 15
• Recognize that prolonged hypoestrogenism causes irreversible bone loss, increased cardiovascular risk, and neurocognitive impairment. [14][15]
• Do not overlook eating disorders, excessive exercise, or psychological stressors as the most common secondary causes of amenorrhea in reproductive‑age women. 14
• Do not delay evaluation beyond 3–6 months of amenorrhea, as early intervention optimizes outcomes. 14

Evaluation of Sexual Activity and Anatomic Causes in Adolescent Amenorrhea

History Assessment

• Screening for a history of sexual activity in adolescents presenting with amenorrhea is essential to evaluate pregnancy risk and to determine whether STI testing is indicated. 16

• Reporting cyclic pelvic pain in a teen with amenorrhea should raise suspicion for outflow‑tract obstruction (e.g., imperforate hymen or vaginal septum). 16

Physical Examination

• A systematic external genital examination is required to detect anatomical abnormalities such as imperforate hymen, vaginal septum, or absent vaginal opening, which can produce primary amenorrhea accompanied by cyclic pain. 16

• Bimanual pelvic examination should be performed only if the patient is sexually active or if an anatomic abnormality is suspected on external inspection. 16

Laboratory Evaluation and Diagnostic Approach for Adolescent Females with Irregular Menstrual Cycles

1. Initial Mandatory Laboratory Tests

• Serum β‑hCG should be obtained first to definitively exclude pregnancy before any further work‑up. 17
• Core endocrine panel (TSH, free T4, morning fasting prolactin, FSH, LH, estradiol) is recommended as the baseline hormonal assessment for menstrual irregularity. 17
• Thyroid function tests (TSH + free T4) are required to rule out thyroid dysfunction, a common reversible cause of abnormal cycles. 17
• Prolactin: fasting morning levels > 20–25 µg/L suggest prolactin‑mediated anovulation; levels > 100 ng/mL mandate pituitary MRI. 17
• FSH and LH drawn during amenorrhea or on cycle days 3‑6: low‑normal < 10 IU/L points to hypothalamic/pituitary dysfunction; FSH > 25‑35 IU/L indicates primary ovarian insufficiency. 17
• Estradiol: persistently low values < 50 pg/mL together with low‑normal gonadotropins support functional hypothalamic amenorrhea. 17
• Anti‑Müllerian hormone (AMH) < 0.5‑1 ng/mL strengthens the diagnosis of primary ovarian insufficiency. 17

2. Conditional Laboratory Tests Based on Clinical Findings

• Total testosterone and DHEA‑S are ordered only when clinical hyperandrogenism is evident (hirsutism ≥ Ferriman‑Gallwey 4‑6, moderate‑severe acne, androgenic alopecia, or virilization). 18
• 8 AM 17‑hydroxyprogesterone > 200 ng/dL should trigger an ACTH stimulation test to evaluate for non‑classic congenital adrenal hyperplasia. 18
• Fasting glucose, 2‑hour OGTT, and lipid panel are recommended when polycystic ovary syndrome (PCOS) is suspected, to screen for insulin resistance and metabolic syndrome. 18
• Pelvic ultrasound may be used to assess polycystic ovarian morphology (≥12 follicles 2‑9 mm per ovary or ovarian volume > 10 mL) in suspected PCOS, but morphology alone is insufficient for diagnosis in adolescents. 18

3. Diagnostic Patterns and Interpretation

• Functional hypothalamic amenorrhea – low‑normal FSH/LH < 10 IU/L, estradiol < 50 pg/mL, normal prolactin, and normal thyroid function. This pattern is a diagnosis of exclusion after ruling out pregnancy, thyroid disease, hyperprolactinemia, PCOS, and primary ovarian insufficiency. 17
• Polycystic ovary syndrome – LH/FSH ratio > 2 with normal or elevated testosterone, oligomenorrhea (cycles > 35 days or < 8 cycles/year persisting > 2 years post‑menarche), and clinical/biochemical hyperandrogenism. Acne alone is not sufficient to define hyperandrogenism in this age group. 18
• Primary ovarian insufficiency – elevated FSH > 25‑35 IU/L with low estradiol < 50 pg/mL; low AMH (<0.5‑1 ng/mL) further supports diminished ovarian reserve. 17
• Hyperprolactinemia – prolactin > 20‑25 µg/L; repeat TSH/free T4 to exclude secondary hyperprolactinemia from hypothyroidism. Prolactin > 100 ng/mL requires brain MRI with pituitary protocol. 17

4. Timing of Evaluation and Clinical Context

• Initiate diagnostic work‑up when menstrual intervals persistently exceed 45 days or when amenorrhea lasts ≥ 3 months. 17
• Do not dismiss oligomenorrhea that continues > 2 years after menarche; it warrants full evaluation. 18
• Recognize that 95 % of adolescents have cycles ≤ 90 days even in the first year after menarche; cycles > 45 days should not be assumed normal. 19

5. Imaging, Bone Health, and Anatomic Assessment

• DEXA scan is indicated when amenorrhea persists ≥ 6 months, or earlier with severe nutritional deficiency, eating disorder, or a history of stress fracture. 17
• Prolonged hypo‑estrogenism during adolescence can cause irreversible bone loss and impair peak bone mass acquisition. 19
• Brain MRI with pituitary protocol is required for severe/persistent headaches, visual changes, galactorrhea, or markedly low/undetectable gonadotropins suggesting pituitary pathology. 17
• External genital examination (and bimanual exam if sexually active) should be performed to exclude anatomical outflow tract anomalies. 17
• Progestin challenge test (medroxyprogesterone 10 mg × 10 days) confirms outflow tract integrity by inducing withdrawal bleeding when estrogen exposure is adequate. 17

6. Key Clinical Pitfalls to Avoid

• Do not order testosterone or DHEA‑S routinely; reserve these assays for adolescents with clear clinical signs of hyperandrogenism. 18
• Do not rely on polycystic ovarian morphology alone to diagnose PCOS in adolescents, as it may represent a normal developmental variant. 18
• Do not delay evaluation beyond 3 months of amenorrhea; early intervention improves bone health and reduces long‑term complications. 17
• Do not overlook eating disorders, excessive exercise, or psychological stressors, which are the most common causes of secondary amenorrhea in this population. 19